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Background: MicroRNAs (miRNAs) are small, non-coding RNAs that regulate protein levels post-transcriptionally.
miRNAs play important regulatory roles in many cellular processes and have been implicated in several diseases.
Recent studies have reported significant levels of miRNAs in a variety of body fluids, raising the possibility that
miRNAs could serve as useful biomarkers. Next-generation sequencing (NGS) is increasingly employed in biomedical
investigations. Although concordance between this platform and qRT-PCR based assays has been reported in high
quality specimens, information is lacking on comparisons in biofluids especially urine. Here we describe the changes
in miRNA expression patterns in a rodent model of renal tubular injury (gentamicin). Our aim is to compare RNA
sequencing and qPCR based miRNA profiling in urine specimen from control and rats with confirmed tubular injury.
Results: Our preliminary examination of the concordance between miRNA-seq and qRT-PCR in urine specimen
suggests minimal agreement between platforms probably due to the differences in sensitivity. Our results suggest
that although miRNA-seq has superior specificity, it may not detect low abundant miRNAs in urine samples.
Specifically, miRNA-seq did not detect some sequences which were identified by qRT-PCR. On the other hand, the
qRT-PCR analysis was not able to detect the miRNA isoforms, which made up the majority of miRNA changes
detected by NGS.
Conclusions: To our knowledge, this is the first time that miRNA profiling platforms including NGS have been
compared in urine specimen. miRNAs identified by both platforms, let-7d, miR-203, and miR-320, may potentially
serve as promising novel urinary biomarkers for drug induced renal tubular epithelial injury.
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There currently are no biomarkers that can accurately
track, correlate, or predict the occurrence of renal injury,
particularly when related to drug-related toxicity [1-3].
There is a growing interest in the role of micro Ribo-
nucleic Acids (miRNAs) in the pathogenesis of renal dis-
eases [4,5] and a growing number of investigations are
directed to characterizing their potential as biomarkers
[6-9]. miRNAs are highly conserved, endogenous, small
(19–25 nucleotides), non-coding RNAs, with the primary* Correspondence: laurence.o.whiteley@pfizer.com
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article, unless otherwise stated.role implicated in post-transcriptional silencing. Since a
single miRNA can regulate multiple transcripts, miRNAs
can potentially impact multiple signaling pathways and
their dysregulation may lead to a variety of different disor-
ders including renal disease [10]. In fact, several miRNAs
have been implicated in various renal diseases, including
diabetic nephropathy, hypertension, glomerulonephritis,
renal cancer, and polycystic kidney disease [11-17]. miR-
NAs are secreted into the circulation by many different
mechanisms including various lipid-containing vesicles,
such as exosomes, microvesicles, and apoptotic bodies,
but can also be protected from degradation by binding to
RNA-binding proteins [9]. Due to their stability, miRNAs
are readily quantified in serum, plasma and other bodytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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characterizing their potential as biomarkers. In fact, study
results from our laboratory and other participating mem-
bers of the Health and Environmental Sciences Institute’s
(HESI) Nephrotoxicity Committee have identified changes
in miRNA levels in various kidney disease animal models.
Although quantitative real-time PCR (qRT-PCR) has most
commonly been used to profile annotated miRNome, newer
technologies which promise increased sensitivity and spe-
cificity are becoming available at astonishing rates. For
example, next-generation sequencing (NGS) is gaining
popularity and has successfully been used to characterize
miRNA profiles in various tissues [18] as well as bio-fluids
including blood and, most recently, cerebral spinal fluid
[19,20]. Although NGS platform has been shown to gener-
ate highly reproducible, accurate data with high correl-
ation to other platforms for high quality RNA samples
[21-24], comparative data on media with low quality and
quantity RNA are lacking.
The objective of this study was to characterize the
miRNA expression changes using two different profiling
platforms in urine specimens following induction of
toxic renal tubular injury in rodents with gentamicin.
Gentamicin is an aminoglycoside antibiotics which like
other nephrotoxicants such as mercuric chloride and
chromium induces injury of renal tubular epithelial cells
[25]. Gentamicin has also been reported to induce more
severe nephrotoxicity than other aminoglycoside antibi-
otics when administered at high doses [26,27] and has
already been shown to induce miRNA changes in rats,
albeit at a different dose and treatment regimen [28]. Ac-
cordingly, we performed a global urinary miRNA expres-
sion profiling using both the more conventional qRT-PCR
TaqMan Low Density Array (TLDA-A, Life Technologies)
method as well as NGS in control and treated rats. The
presence of tubular epithelial injury was confirmed by
histopathology and assessment of a panel of urine protein
biomarkers that have been qualified for use in non-clinical
drug development [29]: kidney injury molecule-1 (KIM-1),
total protein, and beta 2- microglobulin.
Although a recent paper has described NGS characte-
rization of exosomal and non-exosomal miRNAs in
human urine [30], to our knowledge, this is the first time
that the NGS and qRT-PCR based platforms have been
compared in urine. We report that although both plat-
forms were able to identify drug induced changes in
miRNA expression, that there is discordance in the level
of sensitivity of detection. Specifically, with exception
of three miRNAs, miRNA-seq did not detect some
miRNAs which were identified by qRT-PCR with thresh-
old cycle (Ct) values lower than 32 in every urine speci-
men analyzed. These differences could be due to the level
of sensitivity posed by NGS analysis for low abundant
miRNAs which, are easily detected by the qRT-PCRmethod (performed with pre-amplification). On the other
hand, the vast majority of miRNAs detected by NGS were
in their isomeric forms, and thus could not have been
detected by the pre-designed qRT-PCR primers avail-
able on the TLDA-A. Our results suggest that although
miRNA-seq is specific, with few false positive calls, it may
not detect certain low abundant miRNAs in low quality
RNA specimen like those currently obtained from urine.
However, the qRT-PCR analysis will miss a wealth of
information, most importantly in the form of isoforms. In
summary, we have compared the detection of urinary
miRNA alterations in tubular injury with qRT-PCR and
miRNA-seq. Each platform has its strengths and weak-
nesses and therefore, careful considerations should be
made when selecting a platform of choice for urinary
miRNA profiling.
Results
Histopathology and urinary protein biomarker data
indicate gentamicin induced tubular injury at D7 with
50 mg/kg
In order to characterize the miRNA changes that could
be used as biomarkers of acute renal tubular injury, a
study was conducted in the context of the HESI commit-
tee on Biomarkers of Nephrotoxicity in a well-established
rat gentamicin toxicity model. Rats were injected subcuta-
neously daily for seven days with various dose levels of
gentamicin, including 0 and 50 mg/kg/day. Minimal urine
biomarker changes were observed after only 24 hours of
dosing. However, after 7 days of dosing, there were sig-
nificantly increased levels of urine total protein, Beta-2-
Microglobulin and Kim-1 (Figure 1A), consistent with
renal tubular injury.
These urine biomarker levels correlated well with
the histopathological findings, which involved proximal
convoluted tubules (PCT), and to a lesser extent, distal
convoluted tubules (DCT). These changes consisted of
tubular epithelial degeneration and necrosis characterized
by varying degrees of vacuolar and hyaline degeneration,
attenuation, loss of epithelial cellular detail (necrosis), and
detachment from intact basement membranes. Cellular
debris and cellular and hyaline casts were present in
tubular lumens (Figure 1B-C). These changes were as-
sociated with multifocal minimal to mild tubular epi-
thelial regeneration occurring primarily in the PCT,
and were characterized by basophilic cytoplasm, vesicular
nuclei, and infrequent mitoses. In three rats, PCT
degeneration and necrosis was categorized grade 3 (mod-
erate) at Day 7 (Figure 1B) and hence they were se-
lected for further miRNA analysis in the NGS studies.
There were minimal to mild interstitial mononuclear
leukocytic infiltrates. These changes correlated with in-


















































































































































Figure 1 Gentamicin-induced nephrotoxicity in rats. (A) Urinary protein, β2-microglobulin (B2M), and Kim-1 (all normalized to urine creatinine),
indicate tubular injury at D7 (Mean +/− SD; *denotes p value < 0.05). (B) Histopathology assessment of the kidneys revealed moderate degeneration
and necrosis with evidence of regeneration of the PCT at day 7. (C) Section of kidney with moderate degeneration and necrosis of the PCT at day 7;
Control (0 mg/kg/day), top and 50 mg/kg/day bottom. 10 X, H&E stain. Scale bar = 200 microns.
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http://www.biomedcentral.com/1471-2164/15/485Levels of miRNAs in urine significantly changed following
gentamicin induced tubule injury
The transcript levels of 375 miRNAs were measured in
the urine specimen for two time points (day 1 and day
7) after gentamicin treatment by TLDA-A (Figure 2A).
178 miRNAs were detected by qRT-PCR with Ct values
of ≤ 32 in at least 20% of the urine specimen analyzed. Itis important to note that although 178 miRNAs were
actually detected in urine by qRT-pCR only 173 (118 in
rat, 54 in mouse and 1 in human) had a corresponding
identifier in mirBase v 20. Similarly, although 32 urinary
miRNAs changed significantly with gentamicin treat-
ment (>1.5-fold and p < 0.05) seven days post treatment











Figure 2 miRNA expression profiling using Taqman qRT-PCR reveals several significantly changed miRNAs in urine specimens following
gentamicin induced renal injury. (A)Workflow of qRT-PCR analysis. (B) Volcano plot shows 32 miRNAs that are significantly regulated (red) at day 7
after gentamicin treatment (Welch test P-value < 0.05 and FC > 1.5 either direction). miRNAs also detected by NGS are labeled. Horizontal line: P-value
0.05; vertical lines: FC at −1.5 and 1.5. Data are normalized using lowess normalization.
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were up-regulated and 12 were down-regulated. Concor-
dant with the urinary biomarkers analyzed, no significant
miRNA changes were observed at day 1 post gentamicin
treatment (data not shown). Furthermore, no significant
gentamicin induced changes were observed in urine vol-
umes (control: 18.55 ml ± 7.96; Treated: 21.44 ml ± 5.05).
Small RNA Next Generation Sequencing can be used to
evaluate miRNA expression in urinary samples
We next carried out Next Generation sequencing (NGS)
to assess the feasibility of this new technology for analyz-
ing miRNAs in urine samples as compared to the trad-
itional more prevalent qRT-PCR methods widely used.
These cross-comparison studies were performed on seven
control urine samples collected at day 7 from rats with no
tubular injury as well as the three rats from the 50 mg/kggroup from day 7 with the highest (grade 3) level of genta-
micin induced tubular injury (Figure 1B). As depicted in
Figure 3A, after isolating total RNA from the urine speci-
men and checking for RNA extraction quality as well as
quantity, half of each extraction was used in the TLDA
analysis and the other half was sent to Beijing Genomics
Institute of Americas Corporation (BGI, China) for small
RNA sequencing. Table 2 lists the quality and quantity of
the RNA extracted from the urine specimens and depicts
the poor quality as well as low quantity in the 7 control
and 3 gentamicin treated samples. RNA samples were
further processed, including gel selection of Small RNAs
(18 ~ 30 nt), 5' RNA adapter ligation and gel purification,
3' RNA adapter ligation and gel purification, RT-PCR and
gel purification, and despite their low quality did yield a
comprehensive small RNA library which was used in the
sequencing via the Illumina HiSeqTM 2000 (Figure 3A).
Table 1 Of the 173 miRNAs identified in urine specimens by qRT-PCR, 32 miRNAs changed significantly due to treatment
with p-values < 0.05 and ≥ ±1.5 fold-change
Detector name (ABI) Assay ID miRNA ID v. 20 P-value FC miRNA Sequence
mmu-miR-134-4373299 001186 rno-miR-134-5p 0.001 10.83 UGUGACUGGUUGACCAGAGGGG
mmu-miR-342-3p-4395371 002260 rno-miR-342-3p 0.011 4.83 UCUCACACAGAAAUCGCACCCGU
mmu-miR-494-4395476 002365 mmu-miR-494-3p 0.001 4.65 UGAAACAUACACGGGAAACCUC
rno-miR-207-4381096 001315 mmu-miR-207 0.002 3.06 GCUUCUCCUGGCUCUCCUCCCUC
mmu-miR-345-3p-4395659 002529 mmu-miR-345-3p 0.036 3.03 CCUGAACUAGGGGUCUGGAGAC
mmu-miR-193b-4395597 002467 mmu-miR-193b-3p 0.002 2.84 AACUGGCCCACAAAGUCCCGCU
mmu-miR-34a-4395168 000426 rno-miR-34a-5p 0.018 2.74 UGGCAGUGUCUUAGCUGGUUGU
rno-miR-381-4381102 001322 mmu-miR-381-3p 0.047 2.65 UAUACAAGGGCAAGCUCUCUGU
mmu-miR-208-4373091 000511 mmu-miR-208a-3p 0.025 2.57 AUAAGACGAGCAAAAAGCUUGU
mmu-miR-218-4373081 000521 rno-miR-218a-5p 0.028 2.49 UUGUGCUUGAUCUAACCAUGU
mmu-miR-185-4395382 002271 rno-miR-185-5p 0.039 2.44 UGGAGAGAAAGGCAGUUCCUGA
mmu-miR-125b-5p-4373148 000449 rno-miR-125b-5p 0.008 2.08 UCCCUGAGACCCUAACUUGUGA
mmu-miR-140-4373374 001187 rno-miR-140-5p 0.009 1.94 CAGUGGUUUUACCCUAUGGUAG
mmu-miR-16-4373121 000391 rno-miR-16-5p 0.008 1.88 UAGCAGCACGUAAAUAUUGGCG
mmu-miR-489-4378114 001302 mmu-miR-489-3p 0.037 1.78 AAUGACACCACAUAUAUGGCAGC
mmu-miR-208b-4395401 002290 mmu-miR-208b-3p 0.031 1.68 AUAAGACGAACAAAAGGUUUGU
mmu-miR-409-3p-4395443 002332 mmu-miR-409-3p 0.016 1.65 GAAUGUUGCUCGGUGAACCCCU
mmu-miR-320-4395388 002277 rno-miR-320-3p 0.027 1.56 AAAAGCUGGGUUGAGAGGGCGA
mmu-miR-186-4395396 002285 rno-miR-186-5p 0.002 1.5 CAAAGAAUUCUCCUUUUGGGCU
mmu-miR-574-3p-4395460 002349 mmu-miR-574-3p 0.029 1.46 CACGCUCAUGCACACACCCACA
mmu-let-7d-4395394 002283 rno-let-7d-5p 0.002 −1.57 AGAGGUAGUAGGUUGCAUAGUU
mmu-miR-106b-4373155 000442 rno-miR-106b-5p 0.009 −1.65 UAAAGUGCUGACAGUGCAGAU
mmu-miR-363-4378090 001271 mmu-miR-363-3p 0.048 −1.74 AAUUGCACGGUAUCCAUCUGUA
mmu-miR-34b-3p-4395748 002618 rno-miR-34b-3p 0.011 −1.76 AAUCACUAACUCCACUGCCAUC
mmu-miR-23b-4373073 000400 rno-miR-23b-3p 0.001 −2.1 AUCACAUUGCCAGGGAUUACC
mmu-miR-182-4395729 002599 rno-miR-182 0.001 −2.56 UUUGGCAAUGGUAGAACUCACACCG
mmu-miR-30b-4373290 000602 rno-miR-30b-5p 0.023 −2.76 UGUAAACAUCCUACACUCAGCU
mmu-miR-146a-4373132 000468 rno-miR-146a-5p 0.002 −3.21 UGAGAACUGAAUUCCAUGGGUU
mmu-miR-203-4373095 000507 rno-miR-203a-3p 0.037 −3.33 GUGAAAUGUUUAGGACCACUAG
mmu-miR-200c-4395411 002300 mmu-miR-200c-3p 0.000 −3.41 UAAUACUGCCGGGUAAUGAUGGA
mmu-miR-302b-4378071 000531 mmu-miR-302b-3p 0.025 −15.27 UAAGUGCUUCCAUGUUUUAGUAG
mmu-miR-19a-4373099 000395 rno-miR-19a-3p 0.017 −65.54 UGUGCAAAUCUAUGCAAAACUGA
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treated (n = 3) urine specimens, yielded an average of 24
million raw reads/sample. After removing adapter sequen-
ces and filtering out reads too short to be accurately
mapped (less than 18 nucleotides), we obtained on average
22 million clean reads/urine sample (Figure 3B). On aver-
age 99% of the sequences were trimmed and ~96% were
between 16 and 35 nucleotides long (Figure 3C). Figure 4A
shows the breakdown of miRNAs, exons, non-coding
RNA (excluding miRNAs) and unaligned sequences. The
miRNAs formed a very small portion of reads ranging
from 0.1-3% of total reads. As explained in the methodssection, the mapping is dominated by precursors (>60%),
which indicates a lot of heterogeneity in the miRNAs not
accounted for by base substitutions/deletions/insertions at
3’ and 5’ ends. The vast majority of miRNAs detected in
these urine specimens were in fact isomiRs (Figure 4B).
We also observed that there were negligible amounts of
primer-dimers (<3%, data not shown). Exons constituted
11% to as much as 50%. 2-19% of the reads mapped
to other non-coding RNAs including snoRNA, rRNA,
lincRNA, while a major portion of the reads (14-60%)
remained unaligned in the 10 samples and perhaps could
be indicative of contaminants. We next investigated the
Figure 3 Workflow for sequencing and analysis of miRNA changes. (A) Flowchart depicting miRNA sample preparation and sequencing.
After extracting the total RNA from the samples, gel select Small RNA (18 ~ 30 nt), 5' RNA adapter ligation and gel purification, 3' RNA adapter
ligation and gel purification, and RT-PCR and gel purification, the library products were ready for sequencing analysis via Illumina HiSeqTM 2000.
(B) Flowchart depicting bioinformatic processing and analysis. After sequencing, raw reads were cleaned by removing low quality reads and short
reads. Reads were profiled by mapping them to miRBase v. 20 and other sequence databases. (C) Summary (percent) of size distribution of small
RNA sequences in the urinary samples analyzed.
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illustrates that although a substantial portion of miRNAs
aligned to the rat (75-98%), 0.6-17% aligned to the mouse
genome while 0.6-16% mapped to human. Specifically,
227 distinct species of miRNAs were detected: 183 from
rat, 35 from mouse and 9 from human.
We next moved to the cluster and differential expres-
sion analysis (Figure 4B). We observed that clustering
between the groups was lost when the filtering criteria
were altered and we thus had to employ various filtering
criteria to optimize the segregation between control and
gentamicin treated samples. This lack of a clear segrega-
tion suggests that very few miRNAs are differentially
expressed between treated and control samples and that
the miRNAs are expressed at very low levels. Filtering
criterion allowing for inclusion of miRNAs which were de-
tected in at least 2 of 10 samples gave the best segregation(Figure 4D). This yielded 146 miRNAs (121 from rat, 23
from mouse and 2 from human). When we compared the
146 miRNAs detected by NGS to the 173 miRNAs iden-
tified by qRT-PCR, we observed that although 60 were
detected by both platforms, 87 were detected only by
NGS and 111 were specific to TLDA-A.
Additionally, we also investigated the extent of concor-
dance as the percentage of rat miRNAs that are detected
in the control and gentamicin-treated samples analyzed
by both NGS and TLDA-A (Table 3). Out of the total
132 rat-miRNAs detected in TLDA-A 48.52% (64) are
detected in all 7 control samples. Similarly, out of the
168 NGS detected rat miRNAs 22.02% (37) were detec-
ted consistently in all control samples. Thirty five out of
the thirty seven miRNAs consistently detected in all 7
controls by NGS were also detected in all 7 samples by
TLDA-A. However, 33.33% (55) are detected in only 1
Table 2 Urine samples from control (samples 1–7) and
gentamicin treated rats (samples 32, 33, 39) were used
for RNA isolation using the miRNeasy (Qiagen) extraction











1 0 26.4 1.48 0.26 2.0
2 0 42.7 1.57 0.29 2.6
3 0 41.1 1.53 0.2 2.5
4 0 31.1 1.5 0.1 2.2
5 0 41.5 1.61 0.22 2.6
6 0 28.0 1.51 0.23 1.8
7 0 54.1 1.65 0.32 5.4
32 50 44.9 1.71 0.57 2.6
33 50 46.3 1.6 0.18 2.5
39 50 56.9 1.66 0.7 2.6
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Similar investigations from our NGS analysis show that
out of the 183 miRNAs detected, 40% (73) occur in only
isomeric forms and do not have a mature form in miRBase
v20. Twenty one of the seventy three isomeric miRNAs are
detected in 7 samples, whereas 49 (67%) are detected in
only one sample. Interestingly six of these isomeric
miRNAs could potentially also be detected by TLDA-A
as the primers used in the platform may not distinguish
these from their mature forms. Out of 97 miRNAs with
mature forms, 27 are detected in all 7 control urine speci-
men. Similar trends are observed in gentamicin-treated
samples.
Since a large proportion of reads (14-60%) remained
unaligned to rat (Figure 4A), we investigated the origin of
highly represented sequences in the reads that remained
unaligned. In 2 of the 3 gentamicin treated specimen, a
single sequence comprised over 40% of the unaligned
reads. One sample was highly contaminated by a PCR
primer and the other sample was contaminated with a
sequence from the zebrafish. Similarly, in control samples
we observed contamination from a variety of bacterial
and fungal genomes (e.g. from Saccharomyces cerevisiae,
Paenibacillus polymyxa, Ethanoligenens harbinense, Rose-
buria hominis, to name a few). This may indicate fungal
and bacterial contamination during sample collection
or alternatively these contaminations may have been
inadvertently introduced during sample processing
procedures. To what extent these contaminations affected
the NGS results needs to be determined although among
control samples, sample 4 had the least amount of con-
tamination and detected the maximum number (111) of
distinct miRNA species, whereas sample 2 that had the
most contamination contributed 76 miRNAs.We also investigated the possibility that some of these
unaligned reads may have a dietary origin and thus
performed additional mapping to the wheat, corn and
soybean genomes. We observed that a proportion of our
unaligned reads did originate from dietary genomes from
wheat (2%-52%, mean = 19%), corn (0.1%-3.8%, mean =
1.2%) and soybean (0.1%-15%, mean = 3.8%).
Next we investigated various normalization strategies.
Recent literature suggest that miRNA-Seq has its own
challenges and applying the normalization strategies
commonly used in mRNA-seq may need further refine-
ment for use on miRNA sequencing data [31,32]. We
thus compared three different normalization strategies
and three differential analysis methods. DESeq and EdgeR
were applied to their respective normalizations and Limma
was applied to RPM normalized data. EdgeR normalized
values gave the best segregation and gave the maximum
number of overlap with the differentially regulated miR-
NAs identified by qRT-PCR and hence are reported here.
Applying the above described clustering and normali-
zation strategies resulted in identification of 14 diffe-
rentially regulated miRNAs (p-value < 0.05 and ≥ 1.5 fold
change in expression). 9 were up regulated and 5 were
down regulated (Table 4). Three miRNAs, rno-miR-320-
3p, rno-miR-203a-3p, and rno-let-7d-5p, were found to be
significantly altered by both the qRT-PCR and NGS ana-
lysis in the gentamicin treated urine specimens. For these
miRNAs, both platforms reported them to be similarly
regulated; miR-320 was up regulated while let-7d and
miR-203 were down regulated (Tables 1 and 4).
Prediction of miRNA targets and pathway analysis
relevant to renal injury
Ingenuity modeling of the differentially expressed miR-
NAs identified by qRT-PCR and NGS was undertaken to
better understand the targets and pathways regulated.
We ran the predicted miRNA targets from the NGS and
the Taqman qRT-PCR analysis separately through Inge-
nuity’s Tox Function prediction. The main toxicological
functions associated with miRNAs detected by either
platform are Renal Inflammation (pvalue < 1e-6). In ad-
dition, biological functions like cell cycle and cellular
development were associated with miRNAs from both
platforms. Next, pathway analysis was performed using
experimentally verified targets of miRNAs from each
platform. miRNAs from NGS were associated with 200
targets mainly involved with tissue injury & repair, in-
creased levels of red blood cells, and renal necrosis.
miRNAs identified by TLDA-A produced 844 targets
involved in renal inflammation, kidney failure, renal
necrosis, as well as increased levels of red blood cells,
alkaline phosphatase and creatinine. Top pathways inclu-
ded IL6-Signaling (p-value < 2.9e-25) and ERK/MAPK
cascade (p-value < 4.85E-11).
Figure 4 Characterization of miRNAs using NGS. (A) Y-axis represents proportion of total reads. Labels:”miRs”-Reads mapping to miRNAs from
rat, mouse and human, “Exons”-Reads mapping to rat exons, “Other Non-Coding RNA”-Reads mapping to Non-coding RNA (except miRNAs),
“Unaligned”-Reads that could not be aligned to rat genome. (B) Y-Axis represents proportion of the total reads that map to all rat miRNAs
(mature + isomiRs). “Identical”-Reads that are identical to miRNAs, “Perfect Matches”- Reads that are shorter than miRNAs, “1 Extra Base”-Reads that
have an extra base on 3’ and 5’, “1 Substitution”- Reads that have a substitution on 3’ and 5’, “2 Extra Bases”-Reads that have 2 extra bases on 3’
and 5’, “1 Mismatch”-Reads that have at most 1 mismatch (does not include the previous 1 substitution/deletion/insertion), “PremiRs”-Reads that
map the precursor miRNA. (C) Y-Axis gives the proportion of all miRNAs (rat + human +mouse) with maximum value of 1. The rat, mouse and
human miRNAs include mature + isomiRs including precursor miRNAs. (D) Hierarchical clustering of the samples. Spearman correlation coefficient
was used and the method used was “complete”, using the maximal separation.
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for the miRNAs from both profiling platforms, the main
toxicology related function was ‘Nephritis’. Specifically,
two out of the three miRNAs common to both qPCR
and NGS approaches (let-7d and miR-320) mapped to
this function (Figure 5A). We expanded our search for
renal-related functions within the remaining set of diffe-
rentially regulated miRNA’s by examining other renal-Table 3 Percentages of miRNAs detected in control (7)
and gentamicin-treated (3) specimen
Sample 1 2 3 4 5 6 7
Control
NGS 33.33 16.66 5.35 8.33 8.33 5.95 22.02
TLDA 7.87 6.30 6.30 7.87 7.09 15.75 48.82
Gentamicin
NGS 32.75 19.87 47.41
TLDA 19.23 16.15 64.62related associations within the ‘Tox Function’ and ‘Dis-
eases and Bio Functions’ available with IPA analysis. This
led to identification of several additional renal activities,
including a link between the third common miRNA
identified by both platforms, miR-203, and polycystic
kidney disease (Figure 5A). To investigate the potential
targets for the three miRNAs identified by both NGS
and qRT-PCR, network analysis of the genes experi-
mentally linked to let-7d, miR-203 and miR-320 was
investigated. This analysis yielded a number of interesting
genes linked to renal necrosis consistent with gentamicin
induced nephrotoxicity (Figure 5B) which warrant further
investigations in future studies.
Discussion
This study builds on a growing data set indicating that
miRNAs in body fluids can be used as non-invasive
Table 4 Of the 146 miRNAs identified in urine specimens
using NGS analysis, 14 had p-values < 0.05 and ≥ ±1.5
fold-change
miRNA ID FC p-value Sequence
rno-miR-378a-3p 3.1775 0.0002 ACUGGACUUGGAGUCAGAAGG
mmu-miR-5100 -23.7 0.001 UCGAAUCCCAGCGGUGCCUCU
rno-miR-30e-3p 3.9961 0.0031 CUUUCAGUCGGAUGUUUACAGC
rno-miR-125b-2-3p 74.135 0.0049 ACAAGUCAGGCUCUUGGGACCU
rno-let-7d-5p -177.8 0.0084 AGAGGUAGUAGGUUGCAUAGUU
rno-miR-320-5p 92.957 0.01 GCCUUCUCUUCCCGGUUCUUCC
rno-miR-100-5p 10.010 0.012 AACCCGUAGAUCCGAACUUGUG
rno-miR-203a-3p -5.428 0.0158 GUGAAAUGUUUAGGACCACUAG
rno-miR-21-5p 2.4576 0.0241 UAGCUUAUCAGACUGAUGUUGA
rno-miR-3473 -3.990 0.0308 UCUAGGGCUGGAGAGAUGGCUA
rno-miR-21-3p 14.377 0.0329 CAACAGCAGUCGAUGGGCUGUC
hsa-miR-7641 -3.095 0.0359 UUGAUCUCGGAAGCUAAGC
rno-miR-320-3p 2.7415 0.0394 AAAAGCUGGGUUGAGAGGGCGA
rno-miR-455-5p 44.539 0.0405 UAUGUGCCUUUGGACUACAUCG
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physiological conditions. Gentamicin, an aminoglycoside
antibiotic used to treat many types of gram negative bac-
terial infections, is a known nephrotoxicant. The under-
lying mechanism of gentamicin renal toxicity is assumed
to be mainly related to the formation of free hydroxyl
radicals and the inhibition of mitochondrial respiration,
although other mechanisms have also been suggested
[33-36]. The microscopic findings in the kidneys obser-
ved in this study were similar to those previously docu-
mented following administration of gentamicin to rats
[37-39]. Therefore, in this study, gentamicin at a dose of
50 mg/kg/day successfully induced tubular injury 7 days
post treatment (Figure 1). The objective of this study
was to induce nephrotoxicity in rats with gentamicin
and evaluate two miRNA profiling platforms in detecting
significant changes in urine samples.
Sequencing allows for complete evaluation of all small
RNAs, without primer bias or a need for species annota-
tion and as NGS analysis becomes more affordable, more
scientists are choosing this platform in their investigations.
Several studies have examined the concordance between
various profiling platforms including quantitative RT-PCR
and miRNA-seq and although it is generally believed that
for high quality specimens intra-platform variability is
usually minimal, cross-platform comparisons do not ne-
cessarily correlate well [21-24]. Even less is known on
comparisons in biofluids, especially urine. To address this
issue, we have analyzed RNA derived from urine specimen
using Life technologies’ TLDA-A and Illumina’s NGS plat-
forms. We thus prepared small RNA sequencing libraries
using Illumina’s TruSeq sample preparation kit fromurinary total RNA extracted and used on the qRT-PCR
analysis, and sequenced the samples on the HiSeq 2000
(Figure 3). Utilizing NGS allowed us to identify several
kidney-related miRNA which were significantly changed
in rats exposed to the kidney toxicant gentamicin.
However, the majority of miRNAs identified by NGS
were not the same as those identified on TLDA-A cards
(Tables 1 and 4). Thus, we report for the first time, that
there is a minimal agreement between NGS and qRT-PCR
for low yield urinary miRNA analysis.
The observed minimal agreement between the two
platforms could be due to a variety of reasons. One rea-
son could be the fact that we only analyzed miRNAs
available on the TLDA-A, which does not include most
of the miRNAs detected by NGS. TLDA allows for
quantitation of 335 mouse and 226 rat miRNAs based
on Sanger mirBase v. 10 annotations. Out of 375 miRNA
sequences on the TLDA-A, 218 had a corresponding
identifier in Rat mirBase v. 20; 147 in mouse and 1 in
human. 5 TLDA-A miRNAs could not be found in mir-
Base v. 20 as they were deprecated. Out of the 14 miRNAs
that were detected to be differentially expressed using
NGS (Table 4), five (rno-let-7d-5p, rno-miR-100-5p,
rno-miR-203a-3p, rno-miR-21-5p, rno-miR-320-3p) were
represented on the TLDA-A, while nine (rno-miR-378a-3p,
mmu-miR-5100, rno-miR-30e-3p, rno-miR-125b-2-3p, rno-
miR-320-5p, rno-miR-3473, rno-miR-21-3p, rno-miR-455-
5p, and hsa-miR-7641) were not. In fact, these 9 miRNAs
are in their isomeric forms (Figure 4B). This finding high-
lights a key limitation in the qRT-PCR analysis as the
TLDA primers may only detect some isomiRs with extra
bases on either ends, but will miss the isomers with de-
letions/substitutions. Hence, only a subset of miRNAs
are queried on the TLDA-A, and as our results indicate,
nine miRNAs differentially regulated in NGS could not
be detected by the TLDA-A due to its dependency of
primer design. Employing the full TLDA array capabil-
ities to include both A and B cards may improve con-
cordance. The NGS platform, on the other hand, seems
to be highly sensitive to the presence of contaminants.
As observed in this study, contaminations ranging from
PCR primers to bacterial and fungal genomes could
negatively affect detectability of low expressing miRNAs.
Hence the sample with the least amount of contamination
contributed the maximum species of miRNAs compared
to ones with higher contamination. Additionally, as depic-
ted in Table 3, out of the total 132 and 168 rat-miRNAs
detected in TLDA-A and NGS control samples respect-
ively, miRNAs in TLDA-A seem to be far more consist-
ently detected than in NGS.
Although the absence of primer-dimer sequences indi-
cated that there was enough genetic material to sequence, a
large proportion of the reads aligned to non-coding RNAs
(introns, intergenic regions, and exons). Furthermore, a
Figure 5 Prediction of renal functions for miRNA from qPCR and NGS. (A) Analysis of the urinary miRNAs with altered expression in
gentamicin induced tubular injury reveals significant correlations with renal injury. Black filled symbols represent miRNAs identified by qPCR as
significantly changed in renal injury. White filled symbols are miRNAs identified as significantly changed by NGS and the gray filled symbols are
the miRNAs identified as changed in both approaches. Note that Ingenuity’s software combines miRNAs with a common seed sequence to a
single identifier. (B) Potential renal disease related mRNA targets for Let-7d, miR-203, and miR-320 identified by IPA are shown.
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the rat genome, which may indicate the presence of
exogenous RNAs, mRNA degradation, genetic material
expelled through urine, and other contaminants mainly
from dietary, bacterial and fungal origins (Figure 4). For
example, most of the miRNAs that were mapped to
mouse (25) and human (2) can be traced to 3’ regions of
protein coding regions of rat. Furthermore, about 0.6-16%
of detected miRNAs belonged to human and mouse. 24
out of 35 mouse miRNAs and 8 out of 9 human miRNAs
detected in the samples were found in unannotated re-
gions of rat genome. These findings, together with the fact
that the number of miRNAs annotated to the rat is only
about a third compared to human and half as many as in
mouse strongly suggests that the rat miRnome may be
under-annotated.
Another reason for the low concordance between the
2 platforms may be their differences in sensitivity. Specif-
ically, following reverse transcription of miRNA targets,
we performed a pre-amplification step to increase our de-
tection capabilities for the low expressing miRNAs, which
is a step not currently available for the miRNA NGS
analysis. The use of cDNA pre-amplification has been
proposed to increase the sensitivity of miRNA detection,
although with increased variability for low abundant
miRNAs [40,41]. However, all three miRNAs: let-7d,
miR-203, and miR-320 were reliably detected by qRT-PCR
in every sample with low mean Ct values (miR-let-7d:
27.52 ± 0.77; miR-203: 24.66 ± 0.3; miR-320: 24.69 ± 1.1)
which suggests relatively high levels of urinary expres-
sion. Therefore, it is likely that although the qRT-PCR
method will yield a higher level of sensitivity (especially
when combined with the pre-amplification step as was
performed in this study), the NGS may actually provide
higher specificity. Specifically, miRNA-seq did not detect
some miRNAs which qRT-PCR detected (<32 Ct). In our
study we were able to evaluate the NGS samples to a
depth of 10 million reads. It would thus be interest-
ing to examine if increasing the sequencing depth
could improve detection sensitivity and concordance
between the technologies.
These results suggest that although miRNA-seq is spe-
cific, due to its currently stringent RNA input require-
ments, it may not be able to detect certain low quantity
(50 ng) and low quality (OD 260/280 < 1.8; RIN ~ 2)
RNAs in urine at the conditions used in this study (50
base single end sequencing totaling 10 million reads).
Additionally, although total RNA was extracted for each
sample and divided between the TLDA and NGS ana-
lysis, the RNA was further enriched for small RNAs dur-
ing the Illumina Truseq small RNA library preparation.
Just as the pre-amplification step in the TLDA platform
may introduce bias, steps such as RNA ligation may
introduce technical bias during the NGS library construction[42]. None the less, as reported previously, urine in gen-
eral contains very little RNA [43], and this low quality and
quantity of the RNA (as shown in Table 2) might be key
to the low observed concordance between these platforms.
Efforts to improve the quality of RNA to be extracted
from urine specimen may decrease the inter-platform
variability observed. Recently, as more commercially avail-
able kits are designed for this purpose, more investigators
are evaluating the quality as well as quantity of miRNAs
extracted from urine [30]. These investigations together
with improved methodology for enriching of small RNAs
to be used in profiling platforms hold promise for impro-
ved concordance. Furthermore, although in this study we
used cell-free urine probably containing both exosomal as
well as non-exosomal miRNAs, enriching for exosomal
RNAs may also shed light on differences in analysis
between profiling platforms [30].
Therefore, our data suggest that each platform has its
own advantages and disadvantages and their utility should
be decided based on the experimental objectives and study
design limitations. Regardless of platform differences,
the three miRNAs identified by both platforms, let-7d,
miR-203 and miR-320, hold promise as tubular injury
biomarkers due to their strong functional associations
with cellular process or pathways relevant to renal disease.
In fact, the main toxicology related function predicted by
IPA was ‘Renal Nephritis’ (Figure 5A). Looking at each
platform independently, it seems like the differentially
regulated miRNAs identified by TLDA-A, namely miR-16-
5p, 185-5p, 200b-3p, 208a-3p, 23a-3p, 30c-3p, 3118, 494-3p
and 92a-3p which are associated with nephritis (from In-
genuity Pathway Analysis) may be promising biomarkers of
tubule injury. Similarly, miR-100-5p and let-7a-5p impli-
cated in renal inflammation and nephritis may be tubular
injury biomarkers specifically detected by NGS. Taken
together, these results suggest that miRNAs isolated
from urine and profiled by either NGS or qRT-PCR
could potentially serve as translational biomarkers for
detection of some forms of renal injury.
Conclusion
Drug induced kidney injury is not only an unfortunate
clinical manifestation but it also hinders pharmaceutical
progress. Urine samples have the potential to provide a
wealth of information both for clinical applications as
well as translational investigators, and provide a perfect
medium for biomarkers of injury. To our knowledge, this
is the first study comparing urinary miRNA expression
data generated by qRT-PCR to those from sequencing. Al-
though, the high cost of these experiments prohibited us
from performing technical replicates and limited our sam-
ple size (7 control and 3 treated), we were able to evaluate
miRNA expression analysis employing two very different
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that there was high inter-platform concordance.
In summary, we have shown that differentially expressed
urinary miRNAs can be detected by two distinct profiling
platforms, qRT-PCR and miRNA-seq. Our data indicate
that the three miRNAs detected by both technologies may
be useful urinary biomarkers for tubular injury.
Methods
Animals
All animal experiments were conducted in compliance
with the UK Animals (Scientific Procedures) Act 1986
and its associated Guidelines and Codes of Practice.
Studies were reviewed internally by the Pfizer, Sandwich
Ethical Review Process and subsequently authorized by the
UK Home Office as Project Licence 70/6903. Male Sprague
Dawley rats (225-270 g, Charles River Laboratories) were
maintained in a central animal facility housed individually
in polycarbonate cages with autoclaved woodchip bedding
(Lillico) enriched with Lillico paperwool (nesting material).
The room environment was maintained at 21°C ± 2°C and
55 ± 10% relative humidity at all times in an alternating
12-h light–dark cycle. Rats were removed from cages
during surgery, toxicant injection, and blood and urine
collection. Animals were acclimated to the laboratory en-
vironment for a minimum of 5 days prior to initiation of
dosing. Water (purified by reverse osmosis) and Certified
Rodent Diet 5002 (PMI Feeds, Inc.) were provided ad
libitum. Animals were euthanized by isoflurane gas ane-
sthesia followed by exsanguinations.
Dosing
Gentamicin Sulphate (Sigma) [44], in a sterile solution
of 0.9% saline, pH to 7 (adjusted with 1 M NaOH), was
administered by subcutaneous injection once daily to male
rats at doses of 0, 10, 25 and 50 mg/kg/day for 7 days
(maximum of 1 mL per site and no more than 4 sites in
any 24 hour period).
Sample collection
Animals were placed into chilled metabolic cages for
urine collection overnight. All animals were fasted, but
provided free access to water. Total urine volume for
each animal was recorded. Urine was briefly centrifuged
(1000 g for 5 min at 4°C) to sediment any contaminants
and cellular debris and was aliquoted and frozen at −80°C.
Each urine protein biomarker was normalized to the total
amount excreted in the volume of urine collected, and to
the urine creatinine concentration (mg/ml) to normalize
for dilutional effects. There was no change in the amount
of creatinine excreted in the urine of control or treated ani-
mals over the time course of the studies (data not shown).
KIM-1 and Beta-2-Microglobulin were measured using
MSD technology, and urine protein was analyzed usingAdvia 1650 automated technology. Data are expressed as
mean ± standard error. Statistical difference (p < 0.05) was
calculated by one-way ANOVA. p < 0.05 is considered
significant and is represented by a single asterisk (*)
where applicable. All graphs were generated by Prism soft-
ware (GraphPad Software).
Light microscopic examination
Kidneys were weighed at scheduled necropsy, preserved
in 10% neutral buffered formalin, then processed through
graded alcohol and xylene, infiltrated and embedded in
paraffin, sectioned, and stained with hematoxylin and
eosin for histological assessment. Sections for microscopic
evaluation included one coronal section through the middle
third of one kidney and one mid-sagittal section through
the middle third of the other kidney. Histological sections
for both kidneys included cortex, medulla and pelvis. The
agreed upon standardized HESI/PSTC histology lexicon
were used. Histopathology evaluation was performed by a
board certified veterinary pathologist who had knowledge
of the treatment groups and necropsy data (organ weights
and macroscopic observations) but who was blinded as
to clinical pathology datasets, including results from
biomarker evaluations.
RNA extraction and quantitative Polymerase Chain
Reaction (qPCR)
Total RNA was isolated from 200 μL of rat urine using a
modified protocol (miRNeasy RNA extraction kit, Qiagen)
according to the manufacturer’s instructions. Briefly, 700 μL
of QIAzol reagent was added to 200 μL of urine. After
vortexing vigorously with chloroform, the samples were
then centrifuged at 12,000 g for 15 min at 4°C. The upper
aqueous phase was transferred to a new tube and 1.5 vol-
ume of ethanol was added. The sample was then applied
to the column and washed. The immobilized RNA was
then collected from the membrane with 30 μL of RNase
free water.
Total RNA concentration was measured at 260 nm
using a NanoDrop 2000c spectrophotometer (Thermo
Scientific). RNA concentration was further measured for
urine RNA samples on a RNA 6000 Nano chip using
Agilent 2100 Bioanalyzer (Agilent Technologies). This
RNA was used for both the NGS as well the PCR as-
says. Quantitative miRNA analysis was performed using
TaqMan miRNA assays from Applied Biosystems. RNA
was reverse transcribed into complementary DNA (cDNA)
using megaplex primers (16°C for 30 min; 42°C for 30 min;
85°C for 5 min). The cDNA product was then used in a
pre-amplification step. Quantitative PCR was performed
using TaqMan Low Density Array (TLDA A, Life Tech-
nologies) in a Viia7 instrument with the following tem-
perature profile: 95°C for 10 min followed by 40 cycles of
95°C for 15 s and 60°C for 1 min. Only miRNAs that were
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of all the samples were included in the analysis. We
investigated several normalization methods, including
invariant miRNAs, global mean, and lowess using the
Expressionist version 7.6 (Genedata). Welch test was
applied to each normalized data set to assess differential
regulation between control and treated samples. All three
normalization methods yielded similar results in terms of
statistical significance (P-value < 0.05) and fold changes
(FC magnitude > 1.5). However, we report the results
derived from the lowess normalization as it produced the
best match to the NGS data. All graphs were made by
Spotfire DecisionSite (Spotfire Inc.). The miRNAs from
TLDA-A, which are based on mirBase v.10, were mapped
to mirBase v. 20 using their corresponding v.10 sequences.
This allowed us to focus our efforts on the v. 20 miRNA
sequences in our comparative analysis between TLDA-A
and NGS.
NGS analysis
miRNA reads were obtained from BGI. The 3’ and 5’
adaptors were trimmed off the reads and sequences
between 16 and 35 nucleotides of average phred score
of ≥ 30 were retained for further analysis. The reads were
first mapped to rat miRNAs using bowtie [45] without
allowing for mismatches. Instead of discarding the re-
maining reads, we explored the possibilities of RNA
editing to include potential isomiRs [46]. The reads were
thus mapped to miRNAs that have at most 1 base mis-
match, a substitution at the 5’ or 3’ ends, or have 1 or 2
extra bases at either ends. Although 1 base mismatch
would include 1 base substitution/deletion/addition at
the ends, we made sure that 1 base mismatch was inside
the miRNA and that all categories were mutually exclu-
sive. To account for heterogeneity, reads were further
mapped to the precursor miRNAs. Reads that uniquely
mapped to miRNAs were considered and were profiled as:
1) identical to miRNAs, 2) perfectly match to miRNAs
but are of shorter length (no more than 5 bases short),
3) mapping to miRNAs with 1 substitution, 1 or 2 extra
bases at 3’ and 5’ ends and with those with at most 1 mis-
match (occurring inside the sequence and not on ends), 4)
mapping to the precursor miRNA. Thus, steps 2–4 consti-
tute “IsomiRs”-alternative forms of the mature miRNAs.
We merged the counts of reads identical to a miR and
those mapping to Isomeric forms. Additionally, since the
total number of annotated mature miRNAs in rat is 728
compared to 1908 in mouse and 2578 in human, we
accounted for the possibility of miRNA under-annotation
in rat by expanding our mapping to include miRNAs from
mouse and human. Thus, after aligning to rat, the re-
maining reads were further mapped to mouse and
eventually to human miRNAs. MirBase v. 20 was used
for miRNA sequence mapping. Since urine samples maycontain exogenous RNAs and other small RNAs, reads
were also mapped to the RFAM (RNA Families) database
[47] and exon sequences in the rat. The other common
contaminant in miRNA-Seq is primer-dimers which can
adversely affect the quantification of miRNA abundance.
Specifically, the Illumina protocol consists of manual gel
band excision, which enhances the occurrence of primer-
dimers due to incorrect cutting of the gel or insuffi-
cient sample to sequence. We thus included extensive
primer-dimer analysis in our study. Furthermore, since
normalization and differential expression analysis in mRNA-
Seq are still being finalized by the scientific community,
we employed three different widely used methods in our
analysis. We first obtained a Reads per Million (RPM)
count for a miRNA by dividing the number of reads map-
ping to that miRNA by the total number of reads mapping
to all miRNAs and multiplying that by 1,000,000. This
gave the abundance of a miRNA in a million reads. Add-
itionally, the counts were normalized using scaling factors
assuming a negative binomial distribution using DESeq
(Differential Expression for Sequence Count Data) [48]
and trimmed mean normalization using EdgeR (Empirical
analysis of Digital Gene Expression in R) [49] packages in
R-Bioconductor. We next used various filtering criteria
and hierarchical clustering to achieve a clear segregation
between the control and treated samples. Spearman cor-
relation coefficient was used on the normalized values and
a “complete” hierarchical clustering was then performed.
To find the optimum differential analysis we investigated
three different methods [50]: Limma, variants of Fisher’s
exact test from DESeq, and EdgeR packages from the
Bioconductor software. A p-value cutoff of 0.05 was used
for significance detection. In addition, to check for se-
quences that are of dietary origin, all unaligned sequences
were aligned against wheat (Triticum aestivum), corn (Zea
mays) and soybean (Glycine max). Sequences were first
mapped to wheat, then the unaligned sequences were
mapped to corn and then to soybean. The miRNAs from
human and mouse that were detected in the rat samples
were blasted against the rat database in NCBI. Since it also
consisted of miRNAs in only isomeric forms, blast results
that had >85% of the sequence aligned were considered
for further analysis.
Prediction of toxicity effects for NGS/TaqMan significant
miRNAs
The 14 miRNAs identified as significant by NGS and the
32 miRNAs identified by TaqMan were analyzed separ-
ately in Ingenuity System’s Ingenuity Pathway Analysis
IPA tool. IPA Core Analysis was performed on each set
and the most significant ‘Tox Functions’ along with rele-
vant biological functions are reported. Experimentally
verified gene targets were then further evaluated using
IPA’s ‘Core Analysis to extract over-represented biological
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formed on the three conserved miRNAs (let7a-5p,
miR-203-3p, and miR-320b) using IPA’s ‘Grow’ function
to add genes experimentally linked downstream of the
miRNAs via ‘RNA/RNA interactions analysis: miRNA tar-
geting’ relationship. The resulting network was expanded
using the ‘Overlay’ function with IPA’s ‘Ingenuity Tox List’.
The most overlapping list ‘Renal Necrosis/Cell Death’ was
added and the unlinked genes trimmed off for better
visualization.
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